Principal Investigator
Peter Ljubenkov, MD
University of California, San Francisco
- 2 trials
- 1 recruiting now
- 1 compound
Therapeutic focus
- Semantic Dementia
- Frontotemporal Dementia
Recruiting now (1)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT05184569 | Phase 1 | Recruiting | — | Peter Ljubenkov, MD |
All trials (2)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT05184569 | Phase 1 | Recruiting | — | Peter Ljubenkov, MD |
| NCT03987295 | Phase 2 | Completed | Latozinemab | Alector Inc. |
Compounds studied
Trial sites (14)
- Rochester, Minnesota, United States
- San Francisco, California, United States
- Chicago, Illinois, United States
- Houston, Texas, United States
- Philadelphia, Pennsylvania, United States
- London, United Kingdom
- Toronto, Ontario, Canada
- München, Germany
- London, Ontario, Canada
- San Antonio, Texas, United States
- Rotterdam, Netherlands
- Brescia, Italy
- Ulm, Germany
- Amsterdam, Netherlands
Investigator and site data mirrored fromClinicalTrials.gov (public domain).